Optimizing Oral Therapy in Ulcerative Colitis: Removing Error Codes

For people living with ulcerative colitis (UC), a newly available oral therapy, carotegrast methyl (CGM), offers a vital option when standard 5-aminosalicylic acid (5-ASA) agents are insufficient. Approved specifically for patients with moderately active UC, CGM acts as an alpha-4 integrin inhibitor, preventing inflammatory cells from infiltrating intestinal tissue.

The Challenge of Real-World Implementation

However, clinicians, patients, and health systems are confronting a different kind of problem: translating promising trial signals into predictable, timely benefit in routine care without running into logistic and administrative “timeouts.” While phase 3 clinical trials (such as the CT3 trial) demonstrated CGM’s superiority over placebo, real-world evidence has been limited until the recent ASPECT study provided a roadmap for optimizing its use.

Why It Matters

Ulcerative Colitis is a chronic idiopathic disease characterized by recurrent episodes of inflammation in the colorectal mucosa. UC affects the rectum and colon to a variable extent. In 2023, worldwide prevalence was estimated to be approximately 5 million cases.

Beyond physical symptoms like rectal bleeding and abdominal pain, it imposes significant mental challenges, including anxiety, depression, and reduced productivity. Medical management aims to first induce a rapid clinical response and normalize biomarkers, followed by a second aim to maintain clinical remission and reach endoscopic normalisation to prevent long-term disability. General treatments for inducing remission include 5-aminosalicylic acid drugs and corticosteroids. Maintenance treatments include 5-aminosalicylic acid (5-ASA) drugs, thiopurines, biologics (eg, anti-cytokines and anti-integrins), and small molecules (Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators). Over the past several years, therapeutic options have vastly increased, but roughly 10 to 20% of UC patients still require proctocolectomy (surgical removal of the entire colon and rectum) for refractory disease. Researchers and clinicians agree that the key to breaking through the research and development slump will require a combination of pharmacotherapy and personalized medicine.

Matching Patient to Treatment

Recent clinical experience, bolstered by the ASPECT study, highlights that the value of new therapies depends on matching the right patient to the right treatment. The study found that CGM is most effective in patients who have moderate UC but relatively low disease activity, specifically those with a partial Mayo score of less than or equal to 5. Patients with lower baseline Mayo scores (less than or equal to 7) achieved higher clinical remission rates (57.5%) compared to those with higher scores (greater than or equal to 8, 26.8%).

Avoiding the “Clinical Lag”

Slow or imprecise assessment can leave patients exposed to ongoing symptoms and unnecessary steroid exposure. The ASPECT study indicates that symptom improvement is detectable as early as week 2. This rapid signal pushes care toward faster, personalized decision-making. However, if laboratory turnaround for biomarkers or prior authorization processes creates delays, the clinical advantage of this fast-acting oral drug is lost to administrative timeouts.

Who It Affects

A Network of Stakeholders

The Patient: Seeking “Natural” and Convenient Relief

The immediate group affected is those with moderately active UC who have failed 5-ASA agents. For these individuals, an oral therapy like CGM is often preferred over injectable biologics due to ease of administration. The ASPECT study showed that for patients who achieve remission, 56.5% maintain that remission for a full year using only oral 5-ASA agents as maintenance therapy.

The Clinician: Moving Toward Biomarker-Driven Care

Gastroenterologists must adapt their routines to interpret new predictive markers. A significant breakthrough in the ASPECT study is the identification of anti-integrin alpha-nu-beta6 antibody titres.

• Predictive Value: Baseline titres of < 44.6 U/mL predicted higher clinical remission rates (49.1% vs. 26.8%).
• Clinical Utility: Unlike other markers of inflammation, these autoantibodies inhibit proteins involved in colonic epithelial adhesion, offering a unique biomarker profile for CGM responsiveness.

Payers and Systems: The Cost of Delay

A survey conducted with inflammatory bowel disease (IBD) patients identified that healthcare access barriers exist and significantly affect patients. Researchers conducted a 52-question online survey evaluating (1) access to healthcare professionals, medications, and procedures; (2) associated financial challenges; and (3) patient awareness of education and advocacy tools to navigate IBD care barriers. The survey was disseminated through multiple channels to IBD patients and their caregivers. Results showed patients on advanced specialty medications, younger than 65 years of age, or on employer insurance experienced significantly greater issues with insurance barriers to accessing medications and coverage of medically necessary tests/treatments.

Health systems that lack endoscopy capacity see delayed confirmation of mucosal healing. This is where faecal calprotectin (FCP) becomes essential. The ASPECT study found that FCP correlated strongly with the Mayo endoscopic subscore (MES) at the end of treatment (p=0.566). An FCP level of < 387.5 ug/g predicted endoscopic healing (MES 0/1) with a sensitivity of 92%.

What Changes

Protocolizing the Assessment Window

1. The Two-Week Symptom Check*

Clinicians should no longer wait months to evaluate CGM. Because significant differences in stool frequency and rectal bleeding resolution appear by day 11 to day 16, the two-week mark is the new gold standard for initial efficacy evaluation.

• Stool Frequency: Significant improvements over placebo began at day 11.
• Rectal Bleeding: Resolution (subscore of 0) became statistically significant beginning at day 16.

2. Utilizing Non-Invasive Surrogates*

To reduce the burden of invasive colonoscopies, the ASPECT study suggests using a suite of biomarkers.

• FCP: Identified as the most useful surrogate for endoscopic healing.
• LRG (Leucine-rich alpha-2 glycoprotein): A cut-off of 17.0 ug/mL predicted MES 0/1 with 85% sensitivity.
• CRP (C-reactive protein): A cut-off of 0.155 mg/dL served as a comparable, though slightly less sensitive, marker.

3. Streamlining Maintenance Transitions*

Since CGM is not currently approved for maintenance therapy, a clear step-down plan is required. The ASPECT study observed that nearly 80% of patients who achieved remission successfully transitioned to monotherapy with oral 5-ASA agents. The mean dose used at the start of maintenance was 4402 +/- 636 mg.

Detailed Analysis: The Resolution of Rectal Bleeding

A unique contribution of the ASPECT study was the cluster analysis of rectal bleeding resolution. This data allows clinicians to set realistic expectations for patients based on their starting point:

• Cluster 1 (Early Improvement): Most patients starting with a rectal bleeding subscore of 1 achieved rapid resolution.
• Cluster 2 (Intermediate Improvement): Patients with baseline scores of 1 or 2.
• Cluster 3 (Poor Improvement): Primarily patients starting with a high subscore of 3. Only 30% of these patients moved into the improved clusters, suggesting they may need more aggressive initial therapy than CGM alone.

Safety and Operational Vigilance

While CGM demonstrated a favorable safety profile in the CT3 trial, real-world monitoring remains essential. Monitoring for leucine-rich-alpha-2 glycoprotein (LRG) and CRP alongside traditional clinical scoring ensures that silent inflammation is caught even if the patient feels better.

The Role of Shared Decision-Making

Shared decision-making between clinicans and patients with UC is oftentimes complex and takes place in challenging clinical circumstances. Research shows that while shared decision-making can enhance patient-centered care, there’s limited understanding of how this process can be facilitated. Researchers conducted semistructured interviews with UC patients and results showed that patients valued honest, collaborative converstaions with their clinicians.

Care teams must explain that while CGM offers a pill-only path, its success is tied to baseline disease activity. Patients with a partial Mayo score \>5 should be informed that their chance of remission is lower (33.3%) than that of patients with a score of less than or equal to 5 (56.1%). This transparency prevents patient frustration and aligns expectations with clinical reality.

Policy and Reimbursement: Removing the “Error Codes”

Payers that mandate long trial-and-error periods with 5-ASA agents for patients who are clearly moderately active may be increasing overall costs. If a patient is a prime candidate for CGM (e.g., low anti-integrin alpha-nu-beta6 titres and moderate partial Mayo score), delaying access to the drug increases the risk of a severe flare.

Furthermore, reimbursement for FCP and LRG testing must be prioritized. If these markers can reliably predict an MES of 0/1, they can replace expensive and invasive endoscopies, freeing up hospital capacity and reducing the cost-per-patient for insurers.

Looking Forward: Personalizing the Toolkit

Future UC therapeutic management aims to employ more than symptom control and steroid use. However, the unpredictable nature of UC flares and its presentation on different patients emphasizes the insufficiency of standard, one-size-fits-all approach. Precision medicine explores options that surpass outdated standard of care options in favor of innovative pharmacotherapy options.

The ASPECT study has transitioned CGM from a promising new drug to a precision tool. Looking ahead, three developments will reshape practice:

1. Wider Antibody Screening: Integrating anti-integrin alpha-nu-beta6 testing into standard UC workups to identify CGM super-responders.
2. Standardized “Week 2” Protocols: Formalizing clinic visits at the 14-day mark to assess the resolution of rectal bleeding.
3. Refined Maintenance Strategies: Confirming that high-dose 5-ASA (approx. 4.4g) is sufficient to maintain CGM-induced remission for the majority of patients.

A Remedy for “Timeouts”

Ultimately, the clinical community must treat administrative bottlenecks as modifiable risk factors. The ASPECT study proves that when researchers use the right biomarkers (FCP, LRG, and anti-integrin alpha-nu-beta6 antibodies) and the right timing (Week 2 evaluation), CGM is a powerful addition to the UC arsenal.

By framing delays as “error codes” that require systematic fixes, such as rapid-access biomarker testing and streamlined prior authorizations, we ensure that the clinical advantage of this oral therapy produces fast, durable improvements in real-world patients. Without this alignment, the promise of oral integrin inhibition will too often time out before it can truly change a patient’s life.